President & Chief Executive Officer
Karl G. Wassmann is a pioneer in the molecular diagnostic industry for the development and commercialization of blood-based cancer diagnostic tests, including early detection, prognostic and immuno-oncology predictive response tests.
During his 40 year business career, Mr. Wassmann has worked in both the life sciences and high-performance computing fields. Most recently, he served first as Executive Vice President-U.S. Corporate Development of, and then as a cancer diagnostics consultant to, GeneNews Ltd. In those capacities, he focused on commercialization of blood tests for early detection of cancer and developing the pipeline of advanced cancer diagnostic products by the company and its affiliates. Previously, Mr. Wassmann was the Chief Executive Officer of Source MDx, where he managed more than 75 biomarker clinical studies for Pharma clients covering over 20 types of cancer and auto-immune diseases. He also negotiated and led a $15 million multi-year biomarker collaboration with Pfizer, including the development of companion diagnostic biomarkers and evaluating circulating tumor cells. Earlier, Mr. Wassmann was a director or executive officer in several high-tech computer companies, including Wang Laboratories and Encore Computer.
Mr. Wassmann is the co-inventor on numerous molecular diagnostics patents or patent applications including for breast, cervical, colon, lung, melanoma, ovarian and prostate cancers.
Mr. Wassmann is the co-author of several scientific papers (click here) regarding his cancer diagnostics work.
Mr. Wassmann received a B.A. from Bowdoin College and a M.B.A. from the University of Chicago.